Xiang Wei

Hefei, 230011, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

DDR2 ameliorates nonalcoholic hepatic steatosis by activating the AMPK/ACC pathway.

DDR2 ameliorates nonalcoholic hepatic steatosis by activating the AMPK/ACC pathway.

Journal: Scientific reports

Published: October 13, 2025

Mup3 ameliorates the dysregulation of glucose and lipid metabolism in MAFLD.

Mup3 ameliorates the dysregulation of glucose and lipid metabolism in MAFLD.

Journal: Acta pharmacologica Sinica

Published: May 12, 2025

KLF9 drives intermittent hypoxia-induced MASLD by suppressing the NR4A1-p38 MAPK hepatic metabolic axis.

KLF9 drives intermittent hypoxia-induced MASLD by suppressing the NR4A1-p38 MAPK hepatic metabolic axis.

Journal: Hepatology (Baltimore, Md.)

Published: May 02, 2025

Multi-omics based consensus subtypes, development of prognostic signature, and identification of INHBB as a potential therapeutic target in colorectal cancer.

Multi-omics based consensus subtypes, development of prognostic signature, and identification of INHBB as a potential therapeutic target in colorectal cancer.

Journal: Functional & integrative genomics

Published: December 11, 2024

CTSG restraines the proliferation and metastasis of head and neck squamous cell carcinoma by blocking the JAK2/STAT3 pathway.

CTSG restraines the proliferation and metastasis of head and neck squamous cell carcinoma by blocking the JAK2/STAT3 pathway.

Journal: Cellular signalling

Published: September 19, 2024

Bavachin suppresses proliferation of laryngopharyngeal cancer by regulating the STAT3 and MAPK signaling pathways.

Bavachin suppresses proliferation of laryngopharyngeal cancer by regulating the STAT3 and MAPK signaling pathways.

Journal: Journal of Cancer

Published: December 05, 2023

Roles of immune dysregulation in MASLD.

Roles of immune dysregulation in MASLD.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: October 17, 2023

A novel prognostic model for predicting patient survival and immunotherapy responsiveness in hepatocellular carcinoma: insights into the involvement of T-cell proliferation.

A novel prognostic model for predicting patient survival and immunotherapy responsiveness in hepatocellular carcinoma: insights into the involvement of T-cell proliferation.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: September 03, 2023

Knockdown of ACOT4 alleviates gluconeogenesis and lipid accumulation in hepatocytes.

Knockdown of ACOT4 alleviates gluconeogenesis and lipid accumulation in hepatocytes.

Journal: Heliyon

Published: August 08, 2023

FGF9 Recruits β-Catenin to Increase Hepatic ECM Synthesis and Promote NASH-Driven HCC.

FGF9 Recruits β-Catenin to Increase Hepatic ECM Synthesis and Promote NASH-Driven HCC.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: February 20, 2023

Bavachin protects against diet-induced hepatic steatosis and obesity in mice.

Bavachin protects against diet-induced hepatic steatosis and obesity in mice.

Journal: Acta pharmacologica Sinica

Published: September 08, 2022

Development and validation of a novel cellular senescence-related prognostic signature for predicting the survival and immune landscape in hepatocellular carcinoma.

Development and validation of a novel cellular senescence-related prognostic signature for predicting the survival and immune landscape in hepatocellular carcinoma.

Journal: Frontiers in genetics

Published: May 20, 2022

Showing 1-12 of 20

Last Updated: 09/26/2026